Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

CME/CPD

Current issue

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Commentary

Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Frericks N, Kinast V, Steinmann E

Potential risk of porcine-derived pancreatic enzyme medication for the cross-species transmission of hepatitis E virus

Gut Published Online First: 31 May 2024. doi: 10.1136/gutjnl-2024-332577